Cancer and Inflammation Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, National Cancer Institute, Frederick, MD 21702, USA; Sackler Institute of Molecular Medicine, Department of Human Genetics and Molecular Medicine, Sackler School of Medicine, Tel Aviv University, Tel Aviv 69978, Israel.
Cancer and Inflammation Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, National Cancer Institute, Frederick, MD 21702, USA.
Trends Pharmacol Sci. 2014 May;35(5):256-64. doi: 10.1016/j.tips.2014.03.006. Epub 2014 Apr 14.
Orthosteric drugs block the active site to obstruct function; allosteric drugs modify the population of the active state, to modulate function. Available data lead us to propose that allosteric drugs can constitute anchors and drivers. The anchor docks into an allosteric pocket. The conformation with which it interacts is unchanged during the transition between the inactive and active states. The anchor provides the foundation that allows the driver to exert a 'pull' and/or 'push' action that shifts the receptor population from the inactive to the active state. The presence or absence of driver atom in an allosteric drug can exert opposite agonism. We map a strategy for driver identification and expect the allosteric trigger concept to transform agonist/antagonist drug discovery.
变构药物修饰活性状态的构象,从而调节功能;变构药物改变活性状态的构象,从而调节功能。现有数据表明,变构药物可以充当锚点和驱动器。锚点与变构口袋结合。在从无活性状态到活性状态的转变过程中,其与配体相互作用的构象保持不变。锚点为驱动器提供了一个基础,使驱动器能够发挥“拉”和/或“推”的作用,从而将受体从无活性状态转变为活性状态。变构药物中是否存在驱动原子可以产生相反的激动作用。我们提出了一种识别驱动器的策略,并期望变构触发概念能改变激动剂/拮抗剂药物的发现。